TIDMSBTX
RNS Number : 4444N
SkinBioTherapeutics PLC
30 September 2021
30 September 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
AxisBiotix-Ps(TM) Psoriasis Food Supplement Launch and Progress
Update
-- AxisBiotix-Ps(TM) to launch on World Psoriasis Day - 29 October 2021;
-- Finished product ready in Netherlands distribution centre
-- Pre-registrations for AxisBiotix-Ps continue to increase
SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, has today provided a significant update on
its commercialisation plans for AxisBiotix-Ps(TM), its probiotic
food supplement to help alleviate the symptoms associated with
psoriasis, and reveals the launch date as 29 October 2021, which
notably is World Psoriasis Day.
Following highly positive results from its consumer study in May
2021 , SkinBioTherapeutics has driven ahead the finalisation of the
regulatory pathway and commercial strategy for AxisBiotix-Ps (TM) .
Key activities have included the preparation of and warehousing the
finished product and commencing marketing prior to the upcoming
launch, as well as establishing a supply chain.
Through its subsidiary AxisBiotix Limited ("AxisBiotix"),
SkinBioTherapeutics has begun receiving and storing finished
product at its distribution centre in the Netherlands. The
warehouse is 10,000sq metres and is located in Boxtel near
Eindhoven which has been carefully chosen for its proximity to the
Company's formulation partner, Winclove and its distribution links
to the US, UK and Europe. Readying of finished product is ahead of
schedule for launch.
Commercialisation will commence with a 'soft launch' of
AxisBiotix-Ps(TM) on World Psoriasis Day,
29 October 2021. As previously announced, commercialisation will
start in the UK and the US markets. Sales of the product will be
restricted initially to a limited number of customers from the
pre-registration list to ensure a robust and reliable supply chain.
Thereafter access to the eCommerce website will be opened up on a
broader basis to the remainder of the waiting list and the wider
psoriatic population.
As disclosed in the business update on 19 August 2021, excluding
shipping and any duty costs, AxisBiotix-Ps (TM) will be marketed on
a subscription basis and priced per sachet (including VAT) in the
US at $2.00 (USD), in the UK GBP1.50 (GBP), and in Europe EUR1.80
(EUR) and sold in boxes containing 28 sachets.
To create a ready-made market for the product at launch, the
Company has been busily ramping up the profile of the product with
a multi-media marketing strategy to encourage pre-registration of
interest from potential customers. This campaign has included
multiple video testimonials from participants of the consumer study
in May 2021, some of which can be seen HERE . Pre-registration
remains open at this stage and can be accessed via the AxisBiotix
website at axisbiotix.com/form .
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"This is a very exciting moment for SkinBioTherapeutics as we
launch our first commercial product on the most important of days
for the global Psoriasis community. The overall positive response
from participants who identified as having psoriasis to
AxisBiotix-Ps(TM) was tremendous, and we are very grateful for
their continued interest and subsequent support, including their
moving written and video testimonials.
"The soft launch aspect of the commercial strategy is a key
element. Given the incurable and severe nature of psoriasis and the
significant impact on people's lives, we have always said that we
would initially release AxisBiotix-Ps (TM) on a controlled basis to
ensure our distribution systems are robust. We want to ensure a
continuous supply to our customers at all times."
In May 2021 SkinBioTherapeutics reported on the outcomes of the
study for participants that self-identified as suffering from
psoriasis. The results were very positive and provided definitive
support for the commercial development of AxisBiotix-Ps(TM) as a
probiotic food supplement to help alleviate the symptoms of
psoriasis. Of participants that completed the study, 76% reported a
reduction in itchiness and 73% reported that their skin felt less
irritable. For the full report, please see HERE .
-Ends-
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson, Dale Bellis (Sales)
Instinctif Partners (financial press) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Nathan Billis 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Professor
Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors,
the most advanced of which are cosmetic skincare and food
supplements to modulate the immune system by harnessing the
gut-skin axis. In each area SkinBioTherapeutics plans to exemplify
its technology through human studies.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit: www.skinbiotix.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBLGDCGXDDGBC
(END) Dow Jones Newswires
September 30, 2021 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De May 2023 a May 2024